MedPath

Optimization of Immunomodulators and Their Withdrawal After Achievement of Mucosal Healing in Long-term Maintenance of Quiescent Ulcerative Colitis

Not Applicable
Conditions
lcerative Colitis
Registration Number
JPRN-UMIN000036506
Lead Sponsor
Dokkyo Medical University, Department of Gastroenterology.
Brief Summary

A significantly higher remission maintenance rate was observed in the IM continuation group (p??<??0.01). No significant difference was observed between the IM continuation group with a WBC of less than 3000 or a MCV of 100 or greater and the IM continuation group with a WBC of 3000 or greater and a MCV of 99 or lower (p??=??0.08). Higher remission maintenance rates were observed in the IM continuation group of patients for whom MH had been achieved (p??=??0.03).

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
89
Inclusion Criteria

Not provided

Exclusion Criteria

Of the 283 cases, a case where remission had not been achieved within 1 year of the oral administration of immunomodulators, a case with a history of anti-TNF alfa antibody agent administration, a case with less than 80% adherence to immunomodulators were excluded.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary endpoint was the remission maintenance rate following immunomodulators withdrawal indicated by a Mayo endoscopic subscore of 0.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath